Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;38(26):5250-5264.
doi: 10.1038/s41388-019-0790-x. Epub 2019 Mar 20.

AKT drives SOX2 overexpression and cancer cell stemness in esophageal cancer by protecting SOX2 from UBR5-mediated degradation

Zhen Wang  1 , Li Kang  1 , Huifang Zhang  1 , Yuanyong Huang  1 , Lan Fang  1   2 , Menghan Li  1 , Peter J Brown  3 , Cheryl H Arrowsmith  3 , Jiwen Li  4 , Jiemin Wong  5   6
Affiliations

AKT drives SOX2 overexpression and cancer cell stemness in esophageal cancer by protecting SOX2 from UBR5-mediated degradation

Zhen Wang et al. Oncogene. 2019 Jun.

Abstract

As a transcription factor critical for embryonic and adult stem cell self-renewal and function, SOX2 gene amplification has been recognized as a driving factor for various cancers including esophageal cancer. SOX2 overexpression occurs more broadly in cancer than gene amplification, but the mechanism is poorly understood. Here we showed that in esophageal cancer cell lines the levels of SOX2 proteins are not directly correlated to the copy numbers of SOX2 genes and are strongly influenced by proteostasis. We showed that AKT is a major determinant for SOX2 overexpression and does so by protecting SOX2 from ubiquitin-dependent protein degradation. We identified UBR5 as a major ubiquitin E3 ligase that induces SOX2 degradation through ubiquitinating SOX2 at lysine 115. Phosphorylation of SOX2 at threonine 116 by AKT inhibits the interaction of UBR5 with SOX2 and thus stabilizes SOX2. We provided evidence that AKT inhibitor can effectively downregulate SOX2 and suppress esopheageal cancer cell proliferation and stemness. Taken together, our study provides new insight into the mechanism of SOX2 overexpression in cancer and evidence for targeting AKT as a potential therapeutic strategy for SOX2-positive cancers.

PubMed Disclaimer

References

    1. Oncotarget. 2017 Jul 4;8(27):44917-44943 - PubMed
    1. Mol Cancer Res. 2015 Dec;13(12):1523-32 - PubMed
    1. Annu Rev Med. 2016;67:11-28 - PubMed
    1. Oncogene. 2012 May 3;31(18):2270-82 - PubMed
    1. Cancer Cell. 2014 Jul 14;26(1):33-47 - PubMed

Publication types

MeSH terms

LinkOut - more resources